Found: 24
Select item for more details and to access through your institution.
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 91, doi. 10.1007/s10637-021-01142-1
- By:
- Publication type:
- Article
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1275, doi. 10.1007/s10637-020-01025-x
- By:
- Publication type:
- Article
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 500, doi. 10.1007/s10637-013-0060-7
- By:
- Publication type:
- Article
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1236, doi. 10.1007/s10637-013-9942-y
- By:
- Publication type:
- Article
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 623, doi. 10.1007/s10637-012-9843-5
- By:
- Publication type:
- Article
Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
- Published in:
- 2013
- By:
- Publication type:
- Correction notice
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2Â weeks in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 5, p. 453, doi. 10.1007/s10637-007-9071-6
- By:
- Publication type:
- Article
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2006, v. 24, n. 4, p. 311, doi. 10.1007/s10637-005-5055-6
- By:
- Publication type:
- Article
Acute Myeloid Leukemia Unlikely Related to Trabectedin Treatment.
- Published in:
- Acta Haematologica, 2011, v. 126, n. 4, p. 238, doi. 10.1159/000330952
- By:
- Publication type:
- Article
Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis.
- Published in:
- Marine Drugs, 2011, v. 9, n. 6, p. 1007, doi. 10.3390/md9061007
- By:
- Publication type:
- Article
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 5, p. 677, doi. 10.1007/s10637-023-01383-2
- By:
- Publication type:
- Article
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1263, doi. 10.1007/s10637-022-01281-z
- By:
- Publication type:
- Article
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 4, p. 3999, doi. 10.1002/cam4.5250
- By:
- Publication type:
- Article
Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Phase II study of weekly PM00104 (ZALYPSIS) in patients with pretreated advanced/metastatic endometrial or cervical cancer.
- Published in:
- Medical Oncology, 2013, v. 30, n. 3, p. 1, doi. 10.1007/s12032-013-0627-3
- By:
- Publication type:
- Article
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 6, p. 1557, doi. 10.1007/s00280-012-1864-4
- By:
- Publication type:
- Article
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 5, p. 1223, doi. 10.1007/s00280-011-1614-z
- By:
- Publication type:
- Article
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- Journal Article
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 2, p. 182, doi. 10.3390/ph17020182
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study.
- Published in:
- Marine Drugs, 2024, v. 22, n. 4, p. 178, doi. 10.3390/md22040178
- By:
- Publication type:
- Article